HT
CLDX icon

HAP Trading’s Celldex Therapeutics CLDX Stock Holding History

HAP Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,436
Closed -$387K – 824
2015
Q4 		$808K Sell
3,436
-1,388
-29% -$303K 0.04% 308
2015
Q3 		$763K Sell
4,824
-1,589
-25% -$450K 0.04% 305
2015
Q2 		$2.43M Buy
6,413
+193
+3% +$76.6K 0.15% 156
2015
Q1 		$2.6M Buy
+6,220
New +$2.23M 0.18% 125

Other funds holding CLDX

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HAP Trading's CLDX Position: Q1 2016 in Review

HAP Trading sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 3,436 shares — an estimated $387K sold.

HAP Trading first reported a position in CLDX in Q1 2015 and held it in 4 quarters. The position peaked at $2.6M in Q1 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • HAP Trading reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • HAP Trading sold 3,436 Celldex Therapeutics shares in Q1 2016, an estimated $387K.
  • HAP Trading first reported a position in Celldex Therapeutics in Q1 2015 and held it in 4 quarters.
  • HAP Trading's Celldex Therapeutics position peaked at $2.6M in Q1 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on HAP Trading's 13F filing for Q1 2016, filed 12 May 2016.